Last reviewed · How we verify

NCT02180737: Dexmed

Evaluation of Role of Dexmedetomidine as a Sole Agent in Sedation of Cancer Patients Undergoing Radiological Interventional Procedures

Completed Phase 4 Last updated 17 April 2016
What this trial tests

Phase 4 trial testing Dexmeditomedine in Procedural Sedation in 40 participants. Completed in 1 January 2015.

Timeline
1 January 2014
Primary endpoint
1 December 2014
1 January 2015

Quick facts

Lead sponsorNational Cancer Institute, Egypt
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment40
Start date1 January 2014
Primary completion1 December 2014
Estimated completion1 January 2015
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

National Cancer Institute, Egypt

Who can join

Adults 18 to 65, any sex, with Procedural Sedation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Evaluation of the role of dexmedetomidine as a sole agent in sedating patients undergoing interventional radiological procedures and measuring its different outcome variables.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Procedural Sedation

Currently open trials in the same condition.

Other National Cancer Institute, Egypt trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02180737.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing